A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Cytosorbents Corp
CTSO
$20M
Mkt Cap
$0.36
-0.28%
Cytosorbents Corp (CTSO) has a 5-year average return on invested capital (ROIC) of -64.8%. This is below average and may indicate limited pricing power.
Cytosorbents Corp (CTSO) has a market capitalization of $23M. It is classified as a small-cap stock.
Cytosorbents Corp (CTSO) does not currently pay a regular dividend.
Cytosorbents Corp (CTSO) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Cytosorbents Corp (CTSO) reported annual revenue of $36 million in its most recent fiscal year, based on SEC EDGAR filings.
Cytosorbents Corp (CTSO) has a net profit margin of -58.2%. The company is currently unprofitable.
Cytosorbents Corp (CTSO) generated $-15 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Cytosorbents Corp operates in the Surgical & Medical Instruments & Apparatus industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 34M | 36M | 31M | 35M | 43M | 41M |
| Net Income | -11M | -21M | -29M | -33M | -25M | -7.8M |
| EPS | $-0.18 | $-0.38 | $-0.65 | $-0.75 | $-0.57 | $-0.20 |
| Free Cash Flow | -9.9M | -15M | -22M | -34M | -18M | -6.3M |
| ROIC | -133.7% | -81.0% | -112.4% | -81.3% | -39.2% | -9.9% |
| Gross Margin | 77.0% | 70.6% | 70.6% | 59.8% | 74.4% | 73.0% |
| Debt/Equity | 1.61 | 2.65 | 0.89 | 0.52 | 0.43 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -14M | -17M | -32M | -32M | -23M | -10M |
| Operating Margin | -41.9% | -47.2% | -102.8% | -90.9% | -52.7% | -25.3% |
| ROE | -117.3% | -119.8% | -124.6% | -92.8% | -39.2% | -9.9% |
| Shares Outstanding | 63M | 55M | 45M | 44M | 43M | 39M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | N/A | N/A | 4.8M | 9.5M | 15M | 23M | 25M | 41M | 43M | 35M | 31M | 36M | 34M |
| Gross Margin | N/A | N/A | 53.8% | 58.5% | 63.6% | 66.7% | 70.5% | 73.0% | 74.4% | 59.8% | 70.6% | 70.6% | 77.0% |
| R&D | 56M | 2.4M | 3.9M | 4.8M | 3.2M | 7.7M | 12M | 8.8M | 16M | 15M | 16M | N/A | N/A |
| SG&A | 29M | 5.6M | 6.9M | 11M | 15M | 21M | 22M | 28M | 36M | 34M | 38M | 35M | 38M |
| EBIT | -86M | -6.9M | -9.3M | -11M | -9.8M | -16M | -19M | -10M | -23M | -32M | -32M | -17M | -14M |
| Op. Margin | N/A | N/A | -194.2% | -120.6% | -65.0% | -69.3% | -76.0% | -25.3% | -52.7% | -90.9% | -102.8% | -47.2% | -41.9% |
| Net Income | -92M | -19M | -8.1M | -12M | -8.8M | -17M | -19M | -7.8M | -25M | -33M | -29M | -21M | -11M |
| Net Margin | N/A | N/A | -169.7% | -123.5% | -58.1% | -76.5% | -77.2% | -19.1% | -56.9% | -94.6% | -94.1% | -58.2% | -30.8% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | N/M | N/M | N/M | -93.7% | -54.1% | -65.7% | -114.7% | -9.9% | -39.2% | -81.3% | -112.4% | -81.0% | -133.7% |
| ROE | N/A | -469.0% | -99.0% | -879.5% | -85.7% | -101.6% | -563.6% | -9.9% | -39.2% | -92.8% | -124.6% | -119.8% | -117.3% |
| ROA | -2286.1% | -219.5% | -72.3% | -121.3% | -36.5% | -50.3% | -70.4% | -8.7% | -27.4% | -51.9% | -55.2% | -41.3% | -23.1% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | -70M | -6.7M | -9.0M | -6.7M | -6.5M | -11M | -17M | -5.6M | -14M | -28M | -22M | -14M | -9.9M |
| Free Cash Flow | -72M | -6.8M | -9.5M | -6.9M | -7.5M | -12M | -17M | -6.3M | -18M | -34M | -22M | -15M | -9.9M |
| Owner Earnings | -73M | -7.4M | -9.5M | -9.6M | -10.0M | -16M | -19M | -9.8M | -19M | -33M | -27M | -20M | -15M |
| CapEx | 2.5M | 153K | 404K | 141K | 991K | 672K | 698K | 708K | 3.6M | 6.1M | 538K | 284K | 10K |
| Maint. CapEx | 2.6M | 66K | 113K | 162K | 218K | 391K | 582K | 661K | 732K | 883K | 1.5M | 1.6M | 1.5M |
| Growth CapEx | 0 | 88K | 291K | 0 | 772K | 281K | 117K | 48K | 2.9M | 5.2M | 0 | 0 | 0 |
| D&A | 2.6M | 66K | 113K | 162K | 218K | 391K | 582K | 661K | 732K | 883K | 1.5M | 1.6M | 1.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 457K | 696K | 382K | 2.8M | 3.3M | 4.4M | 1.7M | 3.5M | 4.0M | 3.4M | 4.2M | 3.8M | 3.3M |
| Debt Repayment | 0 | 0 | 0 | 119K | 0 | 667K | 0 | 16M | 16M | 16M | 0 | 5.0M | 5.0M |
| Balance Sheet | |||||||||||||
| Net Debt | -1.1M | -3.9M | -7.5M | -4.7M | -21M | -33M | -6.7M | -142M | N/A | -26M | -7.4M | 23M | -505K |
| Cash & Equiv. | 2.2M | 3.6M | 5.3M | 5.2M | 17M | 22M | 12M | 71M | 52M | 22M | 14M | 3.3M | 15M |
| Long-Term Debt | N/A | N/A | 0 | 4.1M | 6.0M | 9.3M | 13M | 0 | N/A | 5.0M | 2.5M | 14M | 15M |
| Debt/Equity | -0.23 | 0.41 | 0.00 | 4.30 | 1.36 | 0.71 | 5.20 | 0.01 | 0.43 | 0.52 | 0.89 | 2.65 | 1.61 |
| Interest Coverage | -203.5 | -22.2 | -1000.3 | -49.6 | -13.1 | -10.7 | -18.4 | -8.6 | -812.1 | -237.7 | -202.3 | -12.0 | -12.0 |
| Equity | -14M | 4.0M | 8.2M | 1.3M | 10M | 17M | 3.4M | 79M | 63M | 35M | 23M | 11M | 9.0M |
| Total Assets | 4.0M | 8.5M | 11M | 9.7M | 24M | 34M | 27M | 90M | 90M | 63M | 53M | 47M | 46M |
| Total Liabilities | 3.1M | 4.5M | 3.0M | 8.4M | 14M | 17M | 24M | 11M | 27M | 28M | 29M | 36M | 37M |
| Intangibles | 360K | 558K | 772K | 1.2M | 1.8M | 2.6M | 3.4M | 4.2M | 4.7M | 4.4M | 3.9M | 3.7M | 3.6M |
| Retained Earnings | -106M | -124M | -133M | -144M | -152M | -170M | -189M | -197M | -221M | -254M | -283M | -304M | -307M |
| Working Capital | 422K | 3.1M | 6.8M | 3.6M | 13M | 21M | 11M | 72M | 51M | 24M | 11M | 12M | 11M |
| Current Assets | 3.5M | 7.6M | 9.9M | 7.8M | 21M | 28M | 21M | 82M | 64M | 34M | 25M | 22M | 21M |
| Current Liabilities | 3.1M | 4.5M | 3.0M | 4.3M | 7.8M | 6.9M | 9.9M | 10M | 14M | 9.7M | 14M | 9.8M | 10M |
| Per Share Data | |||||||||||||
| EPS | -18.75 | -1.29 | -0.33 | -0.46 | -0.32 | -0.56 | -0.60 | -0.20 | -0.57 | -0.75 | -0.65 | -0.38 | -0.18 |
| Owner EPS | -73.78 | -0.52 | -0.39 | -0.38 | -0.36 | -0.51 | -0.59 | -0.25 | -0.44 | -0.74 | -0.61 | -0.36 | -0.23 |
| Book Value | -14.48 | 0.28 | 0.33 | 0.05 | 0.37 | 0.55 | 0.11 | 2.02 | 1.45 | 0.81 | 0.52 | 0.20 | 0.14 |
| Cash Flow/Share | -70.71 | -0.46 | -0.37 | -0.26 | -0.24 | -0.35 | -0.52 | -0.14 | -0.33 | -0.65 | -0.48 | -0.26 | -0.14 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 1.0M | 14.4M | 24.6M | 25.6M | 27.5M | 30.7M | 32.1M | 39.2M | 43.1M | 43.8M | 45.0M | 54.5M | 62.8M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 39.6 | 18.4 | 105.2 | 17.5 | 14.2 | 36.0 | 4.0 | 2.8 | 1.5 | 2.1 | 4.6 | 2.5 |
| Price/Sales | N/A | N/A | 39.4 | 13.0 | 11.0 | 13.5 | 8.0 | 7.5 | 7.9 | 3.0 | 3.8 | 1.5 | 0.7 |
| FCF Yield | N/A | -4.3% | -6.3% | -4.9% | -4.1% | -4.8% | -14.2% | -2.0% | -10.0% | -65.9% | -45.5% | -28.7% | -43.8% |
| Market Cap | 0 | 157M | 151M | 141M | 180M | 240M | 123M | 321M | 177M | 52M | 49M | 51M | 23M |
| Avg. Price | 0.00 | 5.87 | 7.66 | 4.85 | 5.35 | 9.87 | 6.22 | 7.89 | 7.95 | 2.36 | 2.62 | 0.98 | 0.36 |
| Year-End Price | 0.00 | 10.89 | 6.12 | 5.50 | 6.55 | 7.82 | 3.83 | 8.18 | 4.11 | 1.19 | 1.09 | 0.94 | 0.36 |
Cytosorbents Corp passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 69.7%.
Cytosorbents Corp (CTSO) has a debt-to-equity ratio of 2.65. This indicates higher leverage, which may increase financial risk.
Cytosorbents Corp (CTSO) reported earnings per share (EPS) of $-0.38 in its most recent fiscal year.
Cytosorbents Corp (CTSO) has a return on equity (ROE) of -119.8%. A negative ROE may indicate losses or negative equity.
Cytosorbents Corp (CTSO) has a 5-year average gross margin of 69.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 14 years of financial data for Cytosorbents Corp (CTSO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Cytosorbents Corp (CTSO) has a book value per share of $0.20, based on its most recent annual SEC filing.